Bhubaneshwar, Nov. 24 -- Three Indian research institutes have signed an agreement with TechInvention Lifecare Limited for the technology transfer and future commercialisation of a novel TB vaccine candidateThe Indian research institutes are Indian Institute of Technology (IIT)-Bhubaneswar, the Institute of Life Sciences (ILS), Bhubaneswar, and the National Research Development Corporation (NRDC), which have signed the Quadripartite License Agreement (QLA) with TechInvention Lifecare Limited.
The novel TB vaccine candidate is titled "HSP Subunit Vaccine in Adjuvant (DDA) Against Mycobacterium tuberculosis."Tuberculosis (TB) remains one of the world's deadliest infectious diseases, claiming 1.23 million lives in 2024 alone, as reported by t...